Project R-15176

A novel target for PET imaging to predict remyelination. (Research)

The lack of valid and sensitive biomarkers to image repair may explain past failures of therapeutic leads for demyelinating disorders and do not necessarily relate to the clinical efficacy of the compound itself. The issue is particularly relevant for multiple sclerosis (MS), where imaging modalities currently used in trials assess brain inflammation rather than remyelination. Therefore, investing in potential new imaging modalities is crucial for the MS population. Our research group has recently identified a molecule as a driving factor for remyelination, making it an appropriate molecular target for PET tracers to predict myelin repair in MS. In this project, we aim to design a molecular PET imaging probe that can be used as a sensitive predictive biomarker for subsequent remyelination. This will allow to differentiate myelinators from non-myelinators and provide a robust tool to support the clinical development of myelin-promoting agents.

01 November 2024 - 31 October 2026